The primary outcome measure was a composite of death or surgical aortic valve replacement (AVR).
The study end points were (i) the composite of death, stroke or gastrointestinal bleed, (ii) death and (iii) death-censored graft failure.
The primary end point was the composite of death and Q-wave myocardial infarction (QWMI) at 2 years of follow-up.
Event-free survival was measured in years, where "event" was the composite of death, incident stroke and MI.
However, in the overall cohort there were no statistically significant differences in the composite of death or myocardial infarction.
Additionally, peak biomarkers; 90-day mortality; and the composite of death, congestive heart failure (CHF), or cardiogenic shock were assessed.
Efficacy end points included the incidence of death or the composite of death and myocardial infarction (MI) at 30 days.
The primary outcome was a composite of death from any cause or hospitalization for worsening heart failure.
VAP-TF was defined as composite of death attributable to pneumonia and relapse within 28 days of the first episode.
The 3-year incidence of death; cardiac rehospitalization; and a composite of death, myocardial infarction, stroke, cardiac rehospitalization, and revascularization were 13.0%, 43.5%, and 52.2%, respectively.
METHODS AND RESULTS: The primary end point was a composite of death, Q-wave myocardial infarction, and a large reversible thallium defect at 3 years.
